Melanotan II: Broad Melanocortin Activity and Significant Safety Questions

Nonselectivity is central to the risk profile

Melanotan II can activate multiple melanocortin receptors. MC1R activity relates to pigmentation, while central receptors influence appetite, autonomic responses, and sexual function. Broad activity makes effects less predictable.

Limited human research does not support consumer use

Small experimental studies and case reports exist, but Melanotan II is not an FDA-approved tanning, wellness, or sexual-function product. Commercial preparations may have uncertain identity, purity, and concentration.

Reported adverse events are diverse

FDA and published reports describe nausea, flushing, blood-pressure changes, priapism, sympathomimetic toxicity, serious neurologic events, pigment changes, and dermatologic concerns. Case reports cannot establish incidence, but they identify plausible hazards.

Pigment change complicates surveillance

Darkening of nevi or new pigment changes can create clinical uncertainty. Reports discussing melanoma cannot prove causation, but they reinforce the need for caution around unregulated melanocortin exposure.

The route and source add risk

Unapproved injectable material adds sterility, endotoxin, impurity, and dosing risks beyond the intrinsic pharmacology.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.